Who is sponsoring NCT01369771?

NCT01369771 is sponsored by FinnMedi Oy.

What condition does NCT01369771 study?

NCT01369771 studies Ocular Hypertension, Open-Angle Glaucoma.

What drugs are being tested in NCT01369771?

Interventions: Tafluprost 0.0015%.

What is the status of NCT01369771?

NCT01369771 is currently COMPLETED.

Last reviewed 2014-10-27 · How we verify

An Open-label, Phase IV, Pilot Study, to Evaluate Confocal Microscopic Findings of Cornea, Ocular Signs and Symptoms in Patients With OH or OAG Switching From Latanoprost 0.005% to Preservative Free Tafluprost 0.0015% Eye Drops

NCT01369771 Phase 4 COMPLETED

The objective of this study is to investigate corneal confocal microscopic findings, ocular signs and symptoms in patients on treatment with the preserved prostaglandin analogue latanoprost 0.005% eye drops (Xalatan®) and after the switch to preservative-free prostaglandin analog tafluprost 0.0015% eye drops (Taflotan®). Patients who have been using latanoprost as their prior medication (at least 6 months) and who fulfil all the inclusion criteria including the specified ocular symptoms and signs, will switch from latanoprost 0.005% eye drops to the assigned preservative-free tafluprost 0.0015% eye drops for twelve (12) months.

Details

Lead sponsor	FinnMedi Oy
Phase	Phase 4
Status	COMPLETED
Enrolment	30
Start date	2010-08
Completion	2012-06

Conditions

Ocular Hypertension
Open-Angle Glaucoma

Interventions

Tafluprost 0.0015%

Primary outcomes

Change from screening in corneal confocal microscopic findings at month 12 — Baseline and Month 12

Countries

Finland